<DOC>
	<DOC>NCT01771809</DOC>
	<brief_summary>Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 144 weeks of open-label treatment to evaluate the long-term safety of the drug.</brief_summary>
	<brief_title>Long-Term Safety Of PF-00547659 In Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis, Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Subjects between 18 and 66 years of age. Subjects previously enrolled in study A7281009 (NCT01620255) who have completed the 84 day (12 week) induction period. Subjects that have completed Day 84 (Week 12) of study A7281009 but have experienced serious event(s) related to the investigational product, an unstable medical condition, or any other reason, in the opinion of the investigator, would preclude entry or participation in this study. Subjects who are taking any dose of Azathioprine (AZA), 6mercaptopurine(6 MP) or Methotrexate (MTX).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>66 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Anti-TNF Refractory</keyword>
	<keyword>Immunosuppressant Refractory</keyword>
	<keyword>Active Ulcerative Colitis</keyword>
</DOC>